Smerud Knut T, Åsberg Anders, Kile Håkon, Pasch Andreas, Dahle Dag O, Bollerslev Jens, Godang Kristin, Hartmann Anders
Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Smerud Medical Research International AS, Oslo, Norway.
Clin Transplant. 2017 Dec;31(12). doi: 10.1111/ctr.13131. Epub 2017 Oct 26.
A serum test called T assesses the overall propensity for calcification of the blood and is associated with cardiovascular outcomes. We aimed to examine T over time in kidney transplant recipients and also address any effects of ibandronate. Serum samples taken from kidney transplant patients included in a prospective, randomized placebo controlled study of ibandronate were analyzed in retrospect. Adequate analyses were performed at baseline (approximately 3 weeks after transplantation) in 129 patients, at 10 weeks in 127 patients and at 1 year in 123 patients. There were no statistical differences between ibandronate and placebo treatment in terms of T at 10 weeks (P = .094) or at 1 year (P = .116). Baseline T was a significant covariate (P < .0001) for T scores at 10 weeks and 1 year. In the total cohort, there was a highly significant (P < .0001) increase in T of 26.6% after 10 weeks and T remained stable after 1 year. T change was inversely correlated to phosphate of -0.515 (P < .0001) and to change in serum albumin (P < .03). We found that T increased from baseline to 10 weeks after transplantation with no further change after 1 year. Ibandronate had no effect on T .
一种名为T的血清检测可评估血液钙化的总体倾向，且与心血管疾病转归相关。我们旨在观察肾移植受者随时间推移的T水平，并探讨伊班膦酸钠的任何影响。对纳入伊班膦酸钠前瞻性、随机、安慰剂对照研究的肾移植患者采集的血清样本进行回顾性分析。对129例患者在基线时（移植后约3周）、127例患者在10周时以及123例患者在1年时进行了充分分析。在10周时（P = 0.094）或1年时（P = 0.116），伊班膦酸钠组和安慰剂组在T水平方面无统计学差异。基线T是10周和1年时T评分的显著协变量（P < 0.0001）。在整个队列中，10周后T水平显著升高（P < 0.0001），升高了26.6%，1年后T保持稳定。T的变化与磷酸盐呈负相关（-0.515，P < 0.0001），与血清白蛋白的变化呈负相关（P < 0.03）。我们发现，从基线到移植后10周T升高，1年后无进一步变化。伊班膦酸钠对T无影响。
